ROIV
Roivant Sciences Ltd.
Biotechnology
Market Cap$20.91B
5Y Perf.+183.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
ROIV vs KYMR
Revenue, margins, valuation, and 5-year total return — side by side.
KYMR
Kymera Therapeutics, Inc.
Biotechnology
Market Cap$7.04B
5Y Perf.+39.1%
ROIV vs KYMR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ROIV | KYMR |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $20.91B | $7.04B |
| Revenue (TTM) | $13M | $51M |
| Net Income (TTM) | $-809M | $-315M |
| Gross Margin | 91.2% | 33.2% |
| Operating Margin | -91.3% | -7.0% |
| Total Debt | $100M | $82M |
| Cash & Equiv. | $2.72B | $357M |
ROIV vs KYMR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ROIV
KYMR
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| Roivant Sciences Lt… (ROIV) | 100 | 283.4 | +183.4% |
| Kymera Therapeutics… (KYMR) | 100 | 139.1 | +39.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ROIV vs KYMR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ROIV leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Kymera Therapeutics, Inc. is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
ROIV
Roivant Sciences Ltd.
The Income Pick
ROIV carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.95
- Rev growth -11.2%, EPS growth -104.6%, 3Y rev CAGR -19.3%
- 177.1% 10Y total return vs KYMR's 159.4%
Best for: income & stability and growth exposure
KYMR
Kymera Therapeutics, Inc.
The Quality Compounder
KYMR is the clearest fit if your priority is quality and momentum.
- -6.1% margin vs ROIV's -60.8%
- +201.9% vs ROIV's +160.6%
Best for: quality and momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ROIV | -11.2% revenue growth vs KYMR's -16.7% |
| Quality / Margins | KYMR | -6.1% margin vs ROIV's -60.8% |
| Stability / Safety | ROIV | Beta 0.95 vs KYMR's 1.15, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | KYMR | +201.9% vs ROIV's +160.6% |
| Efficiency (ROA) | ROIV | -15.5% ROA vs KYMR's -22.3%, ROIC -50.4% vs -24.9% |
ROIV vs KYMR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
ROIV vs KYMR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLROIVLAGGINGKYMR
KYMRKymera Therapeutics, …
1leads
ROIVRoivant Sciences Ltd.
4leads
6 Total Categories
CATEGORYLEADERvs KYMRMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
KYMR5/6
Valuation MetricsMultiples, price ratios, and targets
ROIV2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ROIV6/8
Total Returns1Y, 3Y, 5Y total returns with dividends
ROIV5/6
Risk & VolatilityBeta, volatility, and downside exposure
ROIV2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
KYMR leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
KYMR is the larger business by revenue, generating $51M annually — 3.9x ROIV's $13M. KYMR is the more profitable business, keeping -6.1% of every revenue dollar as net income compared to ROIV's -60.8%. On growth, KYMR holds the edge at +55.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ROIVRoivant Sciences … | KYMRKymera Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $13M | $51M |
| EBITDAEarnings before interest/tax | -$1.2B | -$352M |
| Net IncomeAfter-tax profit | -$809M | -$315M |
| Free Cash FlowCash after capex | -$767M | -$244M |
| Gross MarginGross profit ÷ Revenue | +91.2% | +33.2% |
| Operating MarginEBIT ÷ Revenue | -91.3% | -7.0% |
| Net MarginNet income ÷ Revenue | -60.8% | -6.1% |
| FCF MarginFCF ÷ Revenue | -57.6% | -4.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -77.8% | +55.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.7% | +13.4% |
KYMR leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
ROIV leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ROIVRoivant Sciences … | KYMRKymera Therapeuti… |
|---|---|---|
| Market CapShares × price | $20.9B | $7.0B |
| Enterprise ValueMkt cap + debt − cash | $18.3B | $6.8B |
| Trailing P/EPrice ÷ TTM EPS | -120.08x | -23.38x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 719.58x | 179.65x |
| Price / BookPrice ÷ Book value/share | 4.03x | 4.61x |
| Price / FCFMarket cap ÷ FCF | — | — |
ROIV leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
ROIV leads this category, winning 6 of 8 comparable metrics.
Profitability & Efficiency
ROIV delivers a -16.3% return on equity — every $100 of shareholder capital generates $-16 in annual profit, vs $-25 for KYMR. ROIV carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to KYMR's 0.05x. On the Piotroski fundamental quality scale (0–9), ROIV scores 5/9 vs KYMR's 4/9, reflecting solid financial health.
| Metric | ROIVRoivant Sciences … | KYMRKymera Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | -16.3% | -25.0% |
| ROA (TTM)Return on assets | -15.5% | -22.3% |
| ROICReturn on invested capital | -50.4% | -24.9% |
| ROCEReturn on capital employed | -16.4% | -27.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.02x | 0.05x |
| Net DebtTotal debt minus cash | -$2.6B | -$275M |
| Cash & Equiv.Liquid assets | $2.7B | $357M |
| Total DebtShort + long-term debt | $100M | $82M |
| Interest CoverageEBIT ÷ Interest expense | — | -2119.53x |
ROIV leads this category, winning 6 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
ROIV leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ROIV five years ago would be worth $29,082 today (with dividends reinvested), compared to $21,049 for KYMR. Over the past 12 months, KYMR leads with a +201.9% total return vs ROIV's +160.6%. The 3-year compound annual growth rate (CAGR) favors ROIV at 47.6% vs KYMR's 46.0% — a key indicator of consistent wealth creation.
| Metric | ROIVRoivant Sciences … | KYMRKymera Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | +31.4% | +18.6% |
| 1-Year ReturnPast 12 months | +160.6% | +201.9% |
| 3-Year ReturnCumulative with dividends | +221.7% | +211.0% |
| 5-Year ReturnCumulative with dividends | +190.8% | +110.5% |
| 10-Year ReturnCumulative with dividends | +177.1% | +159.4% |
| CAGR (3Y)Annualised 3-year return | +47.6% | +46.0% |
ROIV leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
ROIV leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ROIV is the less volatile stock with a 0.95 beta — it tends to amplify market swings less than KYMR's 1.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ROIV currently trades 95.0% from its 52-week high vs KYMR's 83.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ROIVRoivant Sciences … | KYMRKymera Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.95x | 1.15x |
| 52-Week HighHighest price in past year | $30.33 | $103.00 |
| 52-Week LowLowest price in past year | $10.58 | $28.06 |
| % of 52W HighCurrent price vs 52-week peak | +95.0% | +83.7% |
| RSI (14)Momentum oscillator 0–100 | 50.9 | 46.3 |
| Avg Volume (50D)Average daily shares traded | 4.9M | 613K |
ROIV leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates ROIV as "Buy" and KYMR as "Buy". Consensus price targets imply 35.7% upside for KYMR (target: $117) vs 15.2% for ROIV (target: $33).
| Metric | ROIVRoivant Sciences … | KYMRKymera Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $33.20 | $117.06 |
| # AnalystsCovering analysts | 14 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +6.2% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ROIV leads in 4 of 6 categories (Valuation Metrics, Profitability & Efficiency). KYMR leads in 1 (Income & Cash Flow).
Best OverallRoivant Sciences Ltd. (ROIV)Leads 4 of 6 categories
Loading custom metrics...
ROIV vs KYMR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ROIV or KYMR a better buy right now?
For growth investors, Roivant Sciences Ltd.
(ROIV) is the stronger pick with -11. 2% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). Analysts rate Roivant Sciences Ltd. (ROIV) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ROIV or KYMR?
Over the past 5 years, Roivant Sciences Ltd.
(ROIV) delivered a total return of +190. 8%, compared to +110. 5% for Kymera Therapeutics, Inc. (KYMR). Over 10 years, the gap is even starker: ROIV returned +177. 1% versus KYMR's +159. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ROIV or KYMR?
By beta (market sensitivity over 5 years), Roivant Sciences Ltd.
(ROIV) is the lower-risk stock at 0. 95β versus Kymera Therapeutics, Inc. 's 1. 15β — meaning KYMR is approximately 21% more volatile than ROIV relative to the S&P 500. On balance sheet safety, Roivant Sciences Ltd. (ROIV) carries a lower debt/equity ratio of 2% versus 5% for Kymera Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ROIV or KYMR?
By revenue growth (latest reported year), Roivant Sciences Ltd.
(ROIV) is pulling ahead at -11. 2% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Kymera Therapeutics, Inc. grew EPS -23. 8% year-over-year, compared to -104. 6% for Roivant Sciences Ltd.. Over a 3-year CAGR, KYMR leads at -5. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ROIV or KYMR?
Roivant Sciences Ltd.
(ROIV) is the more profitable company, earning -592. 0% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps -592. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KYMR leads at -891. 3% versus -34. 5% for ROIV. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — ROIV or KYMR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ROIV or KYMR better for a retirement portfolio?
For long-horizon retirement investors, Roivant Sciences Ltd.
(ROIV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 95), +177. 1% 10Y return). Both have compounded well over 10 years (ROIV: +177. 1%, KYMR: +159. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ROIV and KYMR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(ROIV: -77.8% · KYMR: 55.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.